First Tracks Biotherapeutics raises $200 million in private placement
1 report, 1 independent
Updated Thu 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
First Tracks Biotherapeutics announced it entered a securities purchase agreement to sell 6,106,870 shares of common stock in a private placement at $32.75 per share. The company anticipates approximately $200 million in gross proceeds, which it plans to use for general corporate purposes, including the clinical development of ANB033. Leerink Partners is acting as a placement agent for the transaction.
From manilatimes.net
Why it matters
The private placement provides significant capital to First Tracks Biotherapeutics to advance its antibody therapeutics. This funding will support the clinical development of its immune pathway modulators.
From manilatimes.net
Who's involved
- Leerink partnersPlacement agent for the private placement of First Tracks Biotherapeutics
Keep exploring
The entities involved
-
Leerink partners
U.S. investment bank
- Kazia Therapeutics Limited is seeking joint bookrunning management and co-management for a proposed offering, with Leerink partners and Needham & Company involved.
- Citigroup raised its rating on Innate Pharma stock, which trades on the Nasdaq exchange. Leerink Partners also upgraded the rating. MarketBeat aggregates the rating data.
Related events
- Leerink Partners is a joint bookrunning manager for an offering by Retension Pharmaceuticals, Inc., with the prospectus available from Boston, MA.
- Leerink Partners is acting as a joint book-running manager for an offering by Spyre Therapeutics, Inc.
- Leerink Partners started coverage on Nautilus Biotechnology on October 6, 2026.
- Leerink Partners, Cantor Fitzgerald, and Barclays acted as placement agents for Atrium on October 8, 2026.